Published in Am J Epidemiol on April 07, 2015
The most important questions in cancer research and clinical oncology-Question 2-5. Obesity-related cancers: more questions than answers. Chin J Cancer (2017) 1.33
Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr (2016) 0.82
Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping. Eur Urol (2016) 0.75
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. Hum Mol Genet (2016) 0.75
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser (2000) 70.59
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Histologic grading of prostate cancer: a perspective. Hum Pathol (1992) 3.36
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res (2006) 2.82
Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol (2008) 2.79
Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (1999) 2.58
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer (2007) 2.29
Obesity as a major risk factor for cancer. J Obes (2013) 2.26
Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr (2007) 2.14
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol (2012) 1.97
Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev (2007) 1.97
Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol (2000) 1.95
Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.77
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res (2010) 1.71
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer (2008) 1.54
Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res (2010) 1.30
Anthropometrics and prostate cancer risk. Am J Epidemiol (2007) 1.25
Androgens and obesity. Curr Opin Endocrinol Diabetes Obes (2010) 1.19
Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev (2008) 1.14
Human ERG-2 protein is a phosphorylated DNA-binding protein--a distinct member of the ets family. Oncogene (1993) 1.04
Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nat Protoc (2008) 1.03
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst (2013) 0.97
Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer (2011) 0.96
The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomarkers Prev (2011) 0.95
Systematic review of prostate cancer's association with body size in childhood and young adulthood. Cancer Causes Control (2008) 0.91
Obesity and prostate cancer incidence and mortality: a systematic review of prospective cohort studies. Urol Int (2013) 0.90
Prostate cancer and body size at different ages: an Italian multicentre case-control study. Br J Cancer (2004) 0.87
Obesity before age 30 years and risk of advanced prostate cancer. Am J Epidemiol (2005) 0.85
Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. Cancer Causes Control (2013) 0.82
Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort. Urology (2013) 0.82
[Prostate cancer: the revolution of the fusion genes]. Actas Urol Esp (2011) 0.80
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 3.58
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst (2003) 3.07
Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev (2008) 3.05
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol (2008) 2.79
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst (2002) 2.54
Pooled results from 5 validation studies of dietary self-report instruments using recovery biomarkers for energy and protein intake. Am J Epidemiol (2014) 2.53
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control (2009) 2.49
Circumcision and the risk of prostate cancer. Cancer (2012) 2.48
Low-fat dietary pattern and change in body-composition traits in the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr (2010) 2.43
Protein intake and incident frailty in the Women's Health Initiative observational study. J Am Geriatr Soc (2010) 2.28
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16
Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc (2003) 2.11
Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev (2007) 2.11
Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J Natl Cancer Inst (2006) 2.08
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Evaluation and comparison of food records, recalls, and frequencies for energy and protein assessment by using recovery biomarkers. Am J Epidemiol (2011) 2.04
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Biomarker-calibrated energy and protein consumption and increased cancer risk among postmenopausal women. Am J Epidemiol (2009) 1.98
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Dietary acculturation: applications to nutrition research and dietetics. J Am Diet Assoc (2002) 1.95
Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst (2013) 1.94
Food nutrition label use is associated with demographic, behavioral, and psychosocial factors and dietary intake among African Americans in North Carolina. J Am Diet Assoc (2005) 1.92
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol (2003) 1.91
Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol (2010) 1.86
Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med (2002) 1.85
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate (2009) 1.83
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
A mathematical model gives insights into nutritional and genetic aspects of folate-mediated one-carbon metabolism. J Nutr (2006) 1.82
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet (2013) 1.78
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol (2011) 1.71
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer (2005) 1.69
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2008) 1.66
Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev (2010) 1.62
Risk factors for renal cell carcinoma in the VITAL study. J Urol (2013) 1.62
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat (2008) 1.60
Nutrient intake and anemia risk in the women's health initiative observational study. J Am Diet Assoc (2011) 1.60
Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.58
Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol (2010) 1.57
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer (2008) 1.54
Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet (2011) 1.54
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev (2011) 1.51
Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.51
Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res (2009) 1.49
Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer (2007) 1.47
Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. PLoS Genet (2011) 1.47
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
Pooled results from 5 validation studies of dietary self-report instruments using recovery biomarkers for potassium and sodium intake. Am J Epidemiol (2015) 1.45
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2008) 1.42
Is olestra consumption associated with changes in dietary intake, serum lipids, and body weight? Nutrition (2003) 1.41
Genetic etiology of hereditary prostate cancer. Front Biosci (2007) 1.41
Cancer prevention behaviors and socioeconomic status among Hispanics and non-Hispanic whites in a rural population in the United States. Cancer Causes Control (2002) 1.41
Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age. Am J Epidemiol (2002) 1.39
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer (2013) 1.37
Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol (2010) 1.36
Comparing indices of diet quality with chronic disease mortality risk in postmenopausal women in the Women's Health Initiative Observational Study: evidence to inform national dietary guidance. Am J Epidemiol (2014) 1.34
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2008) 1.34
Participant characteristics associated with errors in self-reported energy intake from the Women's Health Initiative food-frequency questionnaire. Am J Clin Nutr (2002) 1.33
Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol (2010) 1.33